Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
May 08, 2023 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) --...
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of...
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 25, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating...
Tarsus Announces Transition Plans for Board of Directors
October 11, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s...
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
October 06, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose...
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
September 29, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 ...
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
September 27, 2022 12:00 ET
|
Tarsus Pharmaceuticals, Inc
Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...